Inovio Pharmaceuticals, Inc. (BMV:INO)

Market Cap	2.53B
Revenue (ttm)	3.44M
Net Income (ttm)	-1.66B
Shares Out	n/a
EPS (ttm)	-48.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16
Average Volume	175
Open	47.50
Previous Close	47.00
Day's Range	47.50 - 47.50
52-Week Range	25.00 - 120.00
Beta	n/a
RSI	56.32
Earnings Date	Nov 7, 2025

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 134
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: INO

Financial Performance

In 2024, Inovio Pharmaceuticals's revenue was $217,756, a decrease of -73.83% compared to the previous year's $832,010. Losses were -$107.25 million, -20.62% less than in 2023.

Financial numbers in USD